Reading RVTY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RVTY free→Reading RVTY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RVTY free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, while risk is moderate and the sector backdrop is a headwind. Peer multiples imply a price about 24% below where it trades (it looks expensive on this basis); the read is fair, quality intact. The outlook hinges on guidance changes and sector trends, particularly the performance of key Healthcare bellwethers. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $100.57. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $101 RVTY trades at 29× p/e, in line with its 23× p/e peer median. Our $81 fair value reflects that, low confidence. Analysts: $95–$125. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 24% near-term growth, ahead of our forecast of about 4%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.38x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.28 → $1.22 (-4.8% / 30d). 0 raised, 10 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d. 44% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$120.
How much price usually moves either way.
On a bad day, this stock has moved -$384.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,009.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A miss raises worries about Revvity's growth and market position.
Confirms:Q2 2026 earnings report shows revenue below $740 million.
Disproves:Q2 2026 earnings report shows revenue above $740 million.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for RVTY yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$95.00 – $125.00 (median $108.50) · 4 analysts · as of 2026-05-06
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
RVTY Revvity | Typical Show detailsSector percentile: 66 of 100 | full | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
5 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Revvity plans to divest its Immunodiagnostics business in China, which represented 6% of 2025 revenue.
Revvity aims for pro forma organic revenue growth of 3%-4% in 2026.
Revvity targets pro forma adjusted earnings per share of $5.20-$5.30 for 2026.
Revvity targets adjusted EPS of $5.35-$5.45 for the fiscal year 2026.
Why it matters: Lower organic growth shows market problems. This can hurt investor confidence.
Confirms:Organic revenue growth was below 2% for 2026.
Disproves:Organic revenue growth meets or exceeds 3% for 2026.
Why it matters: Hitting this growth target shows Revvity can handle market challenges. It also shows strong performance.
Confirms:Organic revenue growth reported at or above 3% in Q2 and Q3 2026.
Disproves:Organic revenue growth falls below 2% in either Q2 or Q3 2026.
Why it matters: Strong revenue growth in Q2 would show positive momentum. It would support management's plans.
Confirms:Q2 2026 revenue growth reported at or above 7% year over year.
Disproves:Q2 2026 revenue growth reported below 5% year over year.
Why it matters: Meeting or beating this guidance shows strong profits and good cost management.
Confirms:Adjusted EPS reported at or above $5.35 in Q2 or Q3 2026.
Disproves:Adjusted EPS falls below $5.20 in either Q2 or Q3 2026.
Why it matters: This divestiture is key for Revvity's focus on core operations and growth. It may improve margins and streamline operations.
Confirms:A definitive agreement is signed for the divestiture by the end of Q2 2026.
Disproves:The divestiture is delayed beyond the expected timeline or fails to close.
Other Events Exhibit 99.2 to the Current Report on Form 8-K sets forth the unaudited pro forma condensed consolidated financial statements to present the pro forma financial position and results of operations of Revvity, Inc. and Subsidiaries (the “Company”) based upon historical financial information after giving effect to the probable sale of all of the assets related to the Company’s Immunodiagnostics business in China (“China IDX”) pursuant to a letter of intent signed on April 16, 2026.…
Results of Operations and Financial Condition On February 2, 2026 , Revvity, Inc. announced its financial results for the fourth quarter and fiscal year ended December 28, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or…
Results of Operations and Financial Condition On January 12, 2026, Revvity, Inc. (the “Company”) announced preliminary expectations with respect to certain financial results for the fourth quarter ended December 28, 2025 and announced that the Company will release its fourth quarter and full year 2025 financial results on February 2, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition On October 27, 2025 , Revvity, Inc. announced its financial results for the third quarter ended September 28, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subjec…